Limits...
Global epidemiology of hepatitis C virus infection: An up-date of the distribution and circulation of hepatitis C virus genotypes

View Article: PubMed Central - PubMed

ABSTRACT

Aim: To review Hepatitis C virus (HCV) prevalence and genotypes distribution worldwide.

Methods: We conducted a systematic study which represents one of the most comprehensive effort to quantify global HCV epidemiology, using the best available published data between 2000 and 2015 from 138 countries (about 90% of the global population), grouped in 20 geographical areas (with the exclusion of Oceania), as defined by the Global Burden of Diseases project (GBD). Countries for which we were unable to obtain HCV genotype prevalence data were excluded from calculations of regional proportions, although their populations were included in the total population size of each region when generating regional genotype prevalence estimates.

Results: Total global HCV prevalence is estimated at 2.5% (177.5 million of HCV infected adults), ranging from 2.9% in Africa and 1.3% in Americas, with a global viraemic rate of 67% (118.9 million of HCV RNA positive cases), varying from 64.4% in Asia to 74.8% in Australasia. HCV genotype 1 is the most prevalent worldwide (49.1%), followed by genotype 3 (17.9%), 4 (16.8%) and 2 (11.0%). Genotypes 5 and 6 are responsible for the remaining < 5%. While genotypes 1 and 3 are common worldwide, the largest proportion of genotypes 4 and 5 is in lower-income countries. Although HCV genotypes 1 and 3 infections are the most prevalent globally (67.0% if considered together), other genotypes are found more commonly in lower-income countries where still account for a significant proportion of HCV cases.

Conclusion: A more precise knowledge of HCV genotype distribution will be helpful to best inform national healthcare models to improve access to new treatments.

No MeSH data available.


Related in: MedlinePlus

Anti-hepatitis C virus prevalence (A) and genotype distribution (B) in Europe.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC5016383&req=5

Figure 6: Anti-hepatitis C virus prevalence (A) and genotype distribution (B) in Europe.

Mentions: Central Europe: This large area includes countries like Albania, Bulgaria, Bosnia and Herzegovina, Czech Republic, Croatia, Hungary, Macedonia, Montenegro, Poland, Romania, Serbia, Slovakia and Slovenia, with a prevalence of HCV infection of 1.3%, varying between 1.4% in Slovakia and 0.7% in Czech Republic (Figure 6A) and a viraemic rate estimated at 76.6% (Table 2). We have not found representative data concerning the HCV prevalence and/or HCV viraemic rate from published studies in Albania, Bosnia and Herzegovina, Croatia, Macedonia, Montenegro, Serbia and Slovenia.


Global epidemiology of hepatitis C virus infection: An up-date of the distribution and circulation of hepatitis C virus genotypes
Anti-hepatitis C virus prevalence (A) and genotype distribution (B) in Europe.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC5016383&req=5

Figure 6: Anti-hepatitis C virus prevalence (A) and genotype distribution (B) in Europe.
Mentions: Central Europe: This large area includes countries like Albania, Bulgaria, Bosnia and Herzegovina, Czech Republic, Croatia, Hungary, Macedonia, Montenegro, Poland, Romania, Serbia, Slovakia and Slovenia, with a prevalence of HCV infection of 1.3%, varying between 1.4% in Slovakia and 0.7% in Czech Republic (Figure 6A) and a viraemic rate estimated at 76.6% (Table 2). We have not found representative data concerning the HCV prevalence and/or HCV viraemic rate from published studies in Albania, Bosnia and Herzegovina, Croatia, Macedonia, Montenegro, Serbia and Slovenia.

View Article: PubMed Central - PubMed

ABSTRACT

Aim: To review Hepatitis C virus (HCV) prevalence and genotypes distribution worldwide.

Methods: We conducted a systematic study which represents one of the most comprehensive effort to quantify global HCV epidemiology, using the best available published data between 2000 and 2015 from 138 countries (about 90% of the global population), grouped in 20 geographical areas (with the exclusion of Oceania), as defined by the Global Burden of Diseases project (GBD). Countries for which we were unable to obtain HCV genotype prevalence data were excluded from calculations of regional proportions, although their populations were included in the total population size of each region when generating regional genotype prevalence estimates.

Results: Total global HCV prevalence is estimated at 2.5% (177.5 million of HCV infected adults), ranging from 2.9% in Africa and 1.3% in Americas, with a global viraemic rate of 67% (118.9 million of HCV RNA positive cases), varying from 64.4% in Asia to 74.8% in Australasia. HCV genotype 1 is the most prevalent worldwide (49.1%), followed by genotype 3 (17.9%), 4 (16.8%) and 2 (11.0%). Genotypes 5 and 6 are responsible for the remaining < 5%. While genotypes 1 and 3 are common worldwide, the largest proportion of genotypes 4 and 5 is in lower-income countries. Although HCV genotypes 1 and 3 infections are the most prevalent globally (67.0% if considered together), other genotypes are found more commonly in lower-income countries where still account for a significant proportion of HCV cases.

Conclusion: A more precise knowledge of HCV genotype distribution will be helpful to best inform national healthcare models to improve access to new treatments.

No MeSH data available.


Related in: MedlinePlus